BioCardia
BCDA
8 hedge funds and large institutions have $603K invested in BioCardia in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.04% less ownership
Funds ownership: 0.2% → 0.16% (-0.04%)
11% less funds holding
Funds holding: 9 → 8 (-1)
14% less capital invested
Capital invested by funds: $700K → $603K (-$97K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11.2K |
| 2 |
Morgan Stanley
New York
|
+$2.53K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$71K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51K |
| 3 |
Millennium Management
New York
|
-$38.3K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$1.35K |
BCDA Hedge Fund Activity: Q4 2019 in Review
8 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q4 2019, worth a combined $603K — down 14% from $700K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BCDA and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, opening a new position worth an estimated $11.2K. The largest seller was Goldman Sachs, exiting entirely with an estimated $71K sold.
- 8 institutional investors held BioCardia (BCDA) as of Q4 2019, down from 9 in Q3 2019.
- Funds reported $603K of BioCardia stock for Q4 2019, down 14% quarter-over-quarter.
- 1 fund opened new BioCardia positions in Q4 2019 and 2 closed out, a net change of -1 holder.
- The largest BioCardia buyer in Q4 2019 was UBS Group, an estimated $11.2K added.
- The largest BioCardia seller in Q4 2019 was Goldman Sachs, an estimated $71K sold.
Based on aggregated 13F filings for Q4 2019.